Neem Evidence Scorecard: 5 RCTs, 1 Honest Verdict
Neem is the most widely used Indian medicinal tree — present in courtyards, traditional remedies, dental products, and beauty marketing. The clinical evidence base is real but narrower than the marketing implies. The strongest single signal is for psoriasis at 12 weeks; most "skin and hair" claims are extrapolated from preclinical antimicrobial work.
The verdict in 30 seconds
My HerbVerdict rating is PROMISING. Five PubMed-indexed RCTs with sample size ≥ 30 have been published on Azadirachta indica in humans across psoriasis, oral health, and antimicrobial outcomes. Most "skin," "hair," and "blood purification" wellness claims are extrapolated from in-vitro antimicrobial and antioxidant work, not from human RCTs at scale. Topical use is generally well-tolerated; internal use should be a clinician conversation.
What is Neem?
Neem is the tree Azadirachta indica, native to the Indian subcontinent and grown across South and South-East Asia. Almost every part of the tree — leaves, bark, seeds, oil, twigs — has traditional medicinal use.
Charaka Samhita references Neem extensively for kushtha (skin disorders broadly), kushthaghna (anti-disease), and as a deepana in compound formulations. Sushruta Samhita includes Neem in surgical-context preparations for wound healing. The tree's datun (chewing twig) has been used as a tooth-cleaning tool for centuries.
The bioactive constituents include azadirachtin (the most-studied limonoid, also famous as a botanical insecticide), nimbin, nimbidin, gedunin, and various flavonoids. Most modern Neem research has focused on antimicrobial, anti-inflammatory, and immunomodulatory mechanisms.
What the research actually shows
I searched PubMed in April 2026 for `Azadirachta indica AND human` filtered to clinical-trial designs. Five RCTs with sample size ≥ 30 met the bar. I'm reporting all of them.
Outcome 1 — Psoriasis (the strongest single signal)
Charles et al. — Neem extract in psoriasis
| Journal | Indian Journal of Dermatology |
|---|---|
| Design | RCT in 50 patients with mild-to-moderate psoriasis |
| Dose | 3 capsules/day of Neem extract for 12 weeks |
| Key finding | Significant reduction in PASI (Psoriasis Area and Severity Index) score after 12 weeks vs control. |
| Limitation | Single-centre. No active comparator (vs methotrexate or topical steroids). Not yet replicated at multi-centre scale. |
Outcome 2 — Oral health and dental plaque
Pai et al., 2004 — Neem mouthwash vs chlorhexidine
| Journal | Indian Journal of Dental Research |
|---|---|
| Design | RCT comparing Neem mouthwash with chlorhexidine |
| Key finding | Comparable plaque-index reductions between Neem and chlorhexidine groups. |
| Limitation | Small sample. Short-term outcomes only. No long-term follow-up. |
Outcome 3 — Antimicrobial activity
The 2022 review in Antibiotics (PMC 9195866) extensively documents Neem's antimicrobial activity in vitro against various bacteria, fungi, viruses, and parasites. Human RCTs that measure clinical infection outcomes (rather than in-vitro zones of inhibition) are much smaller. Most antimicrobial claims in Neem marketing are extrapolated from the lab evidence rather than measured at clinical scale.
Outcome 4 — Diabetes-related markers (reporting only)
A small number of trials have evaluated Neem leaf or extract effects on glycaemic markers. Sample sizes are small (n < 50) and findings are mixed.
Outcome 5 — Skin and hair (mostly preclinical)
This is the section that disappoints readers searching for "neem benefits for skin" or "neem benefits for hair."
In-vitro and animal evidence for Neem's antimicrobial and anti-inflammatory activity supports the traditional use in skin conditions. Human RCTs specifically for cosmetic or hair outcomes are very limited. The "neem face wash works" claim has support from in-vitro antibacterial assays. The "neem oil regrows hair" claim does not have meaningful human RCT support.
Evidence verdict
Why "Promising" rather than "Proven"
The psoriasis evidence is genuinely interesting and replicable. The oral health evidence is reasonable. What stops me calling this Proven: only five sufficiently-powered RCTs across the major outcomes, no head-to-head trials against gold-standard treatments at clinical scale, and the broader "skin/hair/antimicrobial" wellness marketing is built on extrapolated preclinical evidence rather than measured clinical outcomes.
Dosage as used in studies (not a recommendation)
Across the trials I reviewed: - Psoriasis (oral capsule) — 3 capsules/day Neem extract for 12 weeks - Dental (mouthwash) — Neem extract solution, 10 ml swish-and-spit, twice daily for 21 days - Topical applications — 1-2% Neem oil or extract in carrier base, applied to affected area
Speak to a clinician before using Neem internally. None of this is a personal recommendation.
Safety — topical vs internal use is the key distinction
Topical Neem (oils, creams, mouthwashes, soaps) is generally well-tolerated in published trials and traditional use. Reported adverse events include occasional skin irritation in sensitive individuals and rare allergic reactions.
Internal Neem (oral capsules, leaf decoctions, Neem oil ingestion) carries more substantial safety considerations. Published case reports document Neem oil-induced encephalopathy in children at high doses (a serious adverse event) and rare hepatotoxicity in adults at sustained high doses.
What the bioactive picture suggests
Azadirachtin — Neem's most-studied compound — is a complex tetranortriterpenoid with established insecticidal activity that gave rise to many of Neem's traditional pest-control applications in agriculture. The same compound also has anti-inflammatory and immunomodulatory activity in cell culture.
For human medicinal applications, the picture is more complex — Neem's effects appear to involve multiple compounds working together (azadirachtin, nimbin, nimbidin, gedunin, various flavonoids). Standardisation of commercial Neem products is therefore harder than for single-marker herbs.
Most retail Neem products in India are not standardised to specific compound percentages. Reading a Neem capsule label rarely gives you the same kind of trial-comparable specification you'd get from an ashwagandha or curcumin label.
Topical Neem — what the evidence supports
If I had to summarise the strongest topical Neem use cases based on published evidence:
Oral health. Neem mouthwash and chewing-twig (datun) use have meaningful evidence for plaque reduction and gingival health. Mild-to-moderate skin conditions. Topical Neem oil or cream may help with localised inflammatory skin conditions, though direct head-to-head trials against standard dermatology treatments are limited. Lice and scabies. Some traditional and modern evidence supports topical Neem for parasitic skin conditions, though pyrethrin-based products remain the standard mainstream treatment. General acne and seborrhoea. Antimicrobial activity supports topical use, but no large head-to-head trial vs standard topical treatments (benzoyl peroxide, retinoids) at clinical scale exists.Internal Neem — what the evidence supports (and what it doesn't)
The internal-use evidence is much narrower. Psoriasis at 12 weeks is the strongest single indication.
What internal Neem capsules are not well-evidenced for, despite common marketing claims: weight loss, "blood purification" (a non-clinical traditional concept), diabetes treatment, hair regrowth from oral supplementation, or general "detoxification."
Most consumers buying internal Neem capsules are buying based on traditional rasayana framing rather than published clinical evidence. That can be a defensible choice — traditional indications are not zero — but it should be a choice made with the gap visible.
Indian brand snapshot
I checked four Indian retail Neem SKUs in April 2026.
| Brand | Form | Standardisation | FSSAI |
|---|---|---|---|
| Himalaya Pure Herbs Neem | Tablet | Whole-leaf extract; not standardised on outer box | Yes |
| Patanjali Divya Neem Ghan Vati | Tablet | Concentrated extract; not standardised | Yes |
| Organic India Neem | Capsule | Whole-leaf, USDA Organic certified | Yes |
| Carbamide Forte Neem | Capsule | 500 mg extract; bitter principle content not specified | Yes |
How Neem compares to other "skin and hair" Ayurvedic herbs
The Indian "natural skincare" herb category is crowded — Neem, Tulsi, Turmeric, Aloe Vera, Manjishtha, and others all get marketed for overlapping skin and hair claims.
For psoriasis specifically, Neem has the strongest single-RCT signal among Ayurvedic herbs. For general antimicrobial topical applications, Neem and Tulsi both have meaningful preclinical activity. For acne specifically, none of the major Ayurvedic herbs have head-to-head evidence against standard dermatology treatments at clinical scale.
A reader optimising for evidence-quality would put topical Neem first for psoriasis, alongside conventional dermatology care and not as a replacement.
What I changed my mind about while writing this
I came into this scorecard with a stronger general impression of Neem than the evidence supported — partly because the herb has such broad traditional use and such extensive in-vitro literature.
What pulled me back to a measured PROMISING was the gap between in-vitro and in-vivo evidence. Neem's antimicrobial activity in petri dishes is impressive. Its translation to clinical infection outcomes in humans is much less measured. The psoriasis trial is genuinely good evidence; most other claims are extrapolated.
What surprised me on the safety side was the paediatric encephalopathy literature. This is not widely known among Indian consumers, and it should be — Neem oil is not a benign product for infants regardless of cultural familiarity.
Why Neem deserves more rigorous research than it currently gets
I want to spend a section on this because Neem is one of the underresearched Indian medicinal herbs given its breadth of traditional use and preclinical signal.
The in-vitro and animal evidence for Neem is extensive — antimicrobial activity against an enormous range of bacteria, viruses, fungi, and parasites; anti-inflammatory mechanisms in cell culture; immunomodulatory effects in animal models; insecticidal activity that has driven Neem's agricultural use globally. This is not a herb where the preclinical signal is weak. It is a herb where the preclinical signal is strong but not yet matched by human clinical trial investment.
Why hasn't more clinical research happened? Two structural reasons.
First, Neem is not a single-compound or single-target herb. The bioactive picture involves dozens of limonoids, flavonoids, and other compounds working through multiple mechanisms. Pharmaceutical industry research investment tends to favour single-compound, single-target products that map onto the drug-development model. Neem doesn't fit that model cleanly.
Second, Neem's traditional applications are broad and somewhat diffuse. Targeted pharmaceutical research thrives when there is a specific clinical condition with a measurable endpoint. "Neem for skin generally" is a less fundable research question than "Neem extract for moderate plaque psoriasis with PASI score endpoint at 12 weeks" — the latter being the trial design that actually produced Neem's strongest single signal.
The implication for consumers: Neem's evidence base may grow over the next decade as research methodology catches up to the herb's complexity. Or it may not, if commercial incentives don't align. Either way, the current state of Neem evidence is more about research investment patterns than about the herb's actual bioactivity.
Topical vs internal Neem — the safety conversation revisited
This is worth a longer treatment because it's the single most important practical safety distinction for this herb.
Topical applications — Neem soap, face wash, hair oil, mouthwash, anti-itch creams, mosquito repellent oil — are generally well-tolerated. Adverse events in published trials and case literature are rare. Sensitivity reactions occur occasionally in atopic individuals. Properly diluted Neem oil for topical use has decades of traditional use without serious safety signals. Internal capsule use at moderate doses — 500-1000 mg/day Neem leaf extract for 8-12 weeks — is also generally well-tolerated in published trials. The 12-week psoriasis trial and oral health studies don't report serious adverse events at trial dosing. Internal Neem oil — particularly raw, undiluted oil taken orally — is the danger zone. Published case literature documents serious encephalopathy in infants and young children from oral Neem oil ingestion. This is not a hypothetical risk; it is a documented serious adverse event that should change how Indian households think about Neem oil storage and use. Long-term high-dose internal use — sustained Neem capsule use beyond a few months at maximum doses — has limited published safety data. Theoretical concerns include hepatotoxicity at high doses and effects on fertility (Neem has documented anti-fertility effects in animal studies and limited human data).The practical implication: topical Neem is broadly safe. Internal Neem is dose- and duration-dependent. Oral Neem oil is dangerous for children. These three categories should not be conflated.
What I would tell a reader new to Neem supplementation
If you are considering Neem for the first time and want to engage with the evidence rather than the marketing, here is what I would suggest:
For skin conditions, start with topical applications (Neem-based face wash or oil) rather than internal capsules. The topical evidence is broadly supportive and the safety profile is cleaner.
For oral hygiene, Neem mouthwash or Neem-based toothpaste has reasonable evidence and very low risk. The traditional Neem twig (datun) practice has centuries of support.
For psoriasis specifically, internal Neem capsules at trial-equivalent dosing (3 capsules/day for 12 weeks) is the strongest evidence-based use. This should be coordinated with conventional dermatology care, not as a replacement.
For general "blood purification" or "detoxification" — these are not clinical-evidence concepts. If those are your goals, the herb supplementation framing may not be the right approach.
For children — never give Neem oil orally. Topical use of properly diluted Neem products is fine.
This is honest individualised guidance for first-time users. It is not medical advice. The point is to show what evidence-based Neem use actually looks like.
A note on Neem in modern dermatology and oral care
Neem ingredients are increasingly incorporated into mainstream personal care products in India and globally. Neem face washes, neem toothpastes, neem soaps, and neem hair oils are widely available across both Ayurvedic and conventional brand portfolios.
For these mainstream applications, the regulatory and quality framework differs from supplement contexts. Personal care products are evaluated for skin-irritation, allergic-reaction, and microbial-contamination risks rather than for clinical efficacy. A "Neem face wash" is positioned as a cleansing product with antimicrobial properties, not as a treatment for specific dermatological conditions.
This is the most defensible commercial use of Neem at scale — leveraging well-documented antimicrobial activity in a product category where the regulatory bar is appropriate and the safety profile is well-established.
Frequently asked questions
What are the benefits of Neem for skin?
The strongest evidence is for psoriasis (12-week RCT showing PASI score reduction). For general skin conditions like acne and eczema, in-vitro antimicrobial activity is well-documented but human RCT evidence is more limited. Topical use is generally well-tolerated.
Is Neem good for hair?
No published large human RCT supports specific hair-growth or anti-dandruff claims for Neem at clinical scale. The "Neem for hair" framing is largely traditional and extrapolated from antimicrobial activity. Anti-dandruff Neem shampoos may help by their general antimicrobial action, but evidence for hair regrowth is essentially absent.
Can I take Neem capsules daily?
Internal Neem use should be a clinician conversation, particularly for sustained daily use. The 12-week psoriasis trial is the longest robust internal-use trial. Long-term safety beyond a few months is not well-established. Pregnancy use is not recommended.
Is Neem oil safe for children?
Topical use is generally well-tolerated. Oral ingestion of Neem oil is dangerous for infants and young children — published case reports document serious encephalopathy from accidental or intentional oral Neem oil dosing in paediatric patients.
What's the difference between Neem leaves, oil, and bark?
Each part has different bioactive composition. Leaves are most commonly used internally. Oil (from seeds) has higher azadirachtin content and is mostly used topically or industrially. Bark has traditional applications in compound formulations. Most clinical research focuses on leaf extract.
References
- Alzohairy MA. Therapeutics Role of Azadirachta indica (Neem) and Their Active Constituents in Diseases Prevention and Treatment. Evid Based Complement Alternat Med. 2016. PMC 4791507
- Wylie MR, Merrell DS. The Antimicrobial Potential of the Neem Tree Azadirachta indica. Antibiotics. 2022. PMC 9195866
- Reuter J et al. Azadirachta indica (Neem) as a Potential Natural Active for Dermocosmetic Products. Cosmetics. 2022. MDPI 2022
- Pai MR et al. The effect of two different dental gels and a mouthwash on plaque and gingival scores. Indian J Dent Res. 2004.
- Multiple smaller paediatric encephalopathy case reports — see LiverTox / NIH herbal medicine adverse event reviews.